CANTA Cantargia AB (publ)
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Otsuka Pharmaceutical Co., Ltd for the clinical IL1RAP targeting antibody CAN10 as well as the preclinical antibody 3G5; and BioWa Inc., granted a nonexclusive license to use the technology platform POTELLIGENT® for the manufacture of the drug candidate nadunolimab. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Cantargia (STO: CANTA)
›
Cantargia (STO: CANTA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 22 employees.
The shares were at 1.280 SEK on 19 November 2026, down 64.6% over 52 weeks. Its 52-week range is 1.250 SEK to 6.590 SEK: the price is 80.6% below the high and 2.4% above the low.
At a market capitalisation of 318.22M SEK, it trades at 1.9 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 94% for CANTA.
Cantargia reports return on equity of 55.3% and an operating margin of 52.5%.
It holds more cash than debt, a net cash position of 221.96M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 25 November 2026.